Loading stock data…
ENLV
$0.82-0.00 (-0.46%)
Market ClosedLast close May 1
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enlivex Ltd. in the Healthcare sector is trading at $0.82. The stock is currently near its 52-week low of $0.66, remaining 22.3% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why ENLV maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.82
Potential Upside
49696.4%
Whystock Fair Value$406.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$20.00+2351.0%
Range$20.00 – $20.00
Fundamentals
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM int...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$218.37M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.04
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.48%
Volume
Today's trading volume
283,210
Recent News
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Enlivex Ltd. is one of the oversold stocksto invest in now. TheFly reported on April 7 that H.C. Wainwright increased its price target on ENLV from $13 to $20 while maintaining a Buy rating. The firm noted that the company […]
Enlivex Therapeutics Q4 Earnings Call Highlights
Enlivex Therapeutics (NASDAQ:ENLV) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline what they described as a “dual-engine” strategy that combines clinical-stage drug development with a digital-asset treasury focused on decentralized prediction markets. Executi
Enlivex Therapeutics announces new listing of RAIN token on Kraken
Enlivex Therapeutics (ENLV) reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset trading platform.President's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFl
Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market
Biopharma firm sets its sights on Rain Protocol’s native token. Rain is an Arbitrum-based prediction market protocol. Prediction markets tipped to reach $96 billion in 10 years.
Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120%
Nasdaq-listed Enlivex Therapeutics has unveiled plans to raise about $212 million in a private placement to build a Rain token-focused digital asset treasury, positioning the project as the first prediction-markets-oriented DAT strategy by a US-listed company. The announcement coincides with a sharp move in the RAIN price on the market, ...